🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

186 results for “Air” Clear

  1. Rybelsus 3 mg tablets, Rybelsus 14 mg tablets, Placebo (semaglutide) tablets, Rybelsus 7 mg tablets

    Novo Nordisk A/S

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  2. Rybelsus 7 mg tablets, Placebo (semaglutide) tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    Novo Nordisk A/S

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  3. The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study

    GlaxoSmithKline Biologicals S.A.

    Asthma with type 2 inflammation characterized by an eosinophilic phenotype

    phase 3 other active

    1 trial

  4. VX-880 solution for infusion

    Vertex Pharmaceuticals (Ireland) Limited

    Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia

    phase 3 small molecule active

    1 trial

  5. Xolair 150 mg solution for injection in pre-filled syringe, Placebo, solution for injection in pre-filled syringe, BP11

    CuraTeQ Biologics s.r.o

    Chronic Urticaria

    phase 3 small molecule active

    1 trial

  6. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, FLUOROURACIL, OPDIVO 10 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion, DISODIUM FOLINATE

    Bristol-Myers Squibb / Pfizer EEIG

    Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)

    phase 3 small molecule active

    1 trial

  7. 60 mg Prednisone

    United Therapeutics Europe Ltd

    Airway Inflammation

    phase 2 small molecule completed

    1 trial

  8. A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

    GlaxoSmithKline Biologicals S.A.

    Neoplasms, Colorectal

    phase 2 other active

    1 trial

  9. A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis

    Pharma Mar S.A.

    Primary Hyperoxaluria

    phase 2 other active

    1 trial

  10. AIR DNase™

    Protalix BioTherapeutics

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial

  11. Advair HFA

    United Therapeutics Europe Ltd

    Altitude Edema

    phase 2 small molecule active

    1 trial

  12. Air médical en bouteille, OXYGEN

    Pari Pharma GmbH

    Alternating Hemiplegia of Childhood

    phase 2 small molecule active

    1 trial

  13. Amyvid 800 MBq/mL solution for injection, ACU193 matching Placebo, Neuraceq 300 MBq/mL solution for injection, ACU193, VIZAMYL 400 MBq/mL solution for injection

    Acumen Pharmaceuticals

    Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)

    phase 2 small molecule active

    1 trial

  14. Atorvastatin Oral Tablet

    PRECISION BIOSCIENCES INC

    Mild Cognitive Impairment

    phase 2 small molecule active

    1 trial

  15. Avastin 25 mg/ml concentrate for solution for infusion., Vectibix 20 mg/ml concentrate for solution for infusion, Folinato Cálcico Hikma, 10 mg/ml solución inyectable y para perfusión EFG, Oxaliplatino Kabi 5 mg/ml concentrado para solución para perfusión EFG, Erbitux 5 mg/mL solution for infusion, Irinotecan Hydrochloride Trihydrate Fair-Med Healthcare 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG

    Disc Medicine

    Colorectal cancer and metastatic disease limited to the liver with bad prognosis.

    phase 2 small molecule active

    1 trial

  16. BIS-001ER

    SUPERNUS PHARMACEUTICALS, INC.

    Focal Impaired Awareness Seizures

    phase 2 small molecule active

    1 trial

  17. Balstilimab, CR6086, CR6086

    Pharm Research Associates (UK) Limited

    Pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer, and other metastatic GI cancers

    phase 2 small molecule active

    1 trial

  18. CLAIRYG 50 mg/ml, solution pour perfusion, MESNA EG 100 mg/ml, solution injectable pour perfusion, CYCLOPHOSPHAMIDE SANDOZ 1000 mg, poudre pour solution injectable ou pour perfusion, SOLUMEDROL 1 g, poudre et solvant pour solution injectable

    Pari Pharma GmbH

    paraneoplastic sensory neuropathy with anti-Hu antibodies

    phase 2 small molecule active

    1 trial

  19. CYCLOPHOSPHAMIDE MONOHYDRATE, BORTEZOMIB, ISATUXIMAB, LENALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE

    Ology Bioservices Ireland LTD

    Newly diagnosed patients with multiple myeloma and severe renal impairment

    phase 2 small molecule active

    1 trial

  20. Febuxostat

    Takeda Pharmaceuticals International AG

    Renal Impairment

    phase 2 small molecule completed

    1 trial

  21. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.

    Disc Medicine

    Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).

    phase 2 small molecule active

    1 trial

  22. JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    DNA repair-deficient or platinum-sensitive solid tumors

    phase 2 small molecule active

    1 trial

  23. KALINOX 50%/50%, gaz medicinal comprime, Medical Air

    Tour Hekla

    Treatment of suicidal ideation

    phase 2 small molecule active

    1 trial

  24. KALINOX 50%/50%, gaz medicinal comprime, Medical Air

    Tour Hekla

    psychiatry

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources